Skip to main content

What is the difference between Amjevita and Humira?

Medically reviewed by Melisa Puckey, BPharm. Last updated on Oct 31, 2023.

Official Answer by Drugs.com

Amjevita (adalimumab-atto) is a biosimilar to Humira (adalimumab), an anti-TNF-α monoclonal antibody used for the treatment of multiple conditions including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, plaque psoriasis, and hidradenitis suppurativa.

A biosimilar is a product that is highly similar to an FDA-approved biologic, known as the reference product. Biosimilars have no clinically meaningful differences in safety, purity or potency compared to the reference product.

Amjevita (adalimumab-atto) was the first Humira (adalimumab) biosimilar approved by the FDA.

FDA approved biosimilars to Humira include:

For more information, details and comparison tables of brands of Humira see adalimumab.

The approved indications for Humira and Amjevita are not the same.

Like Humira, Amjevita is used for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa and Uveitis.

Indications may also differ across age groups groups.

The following table compares the approved indications for Humira and Amjevita:

Indication Humira Amjevita
Rheumatoid Arthritis (RA) adults adults
Juvenile Idiopathic Arthritis (JIA) patients 2 years of age
and older
patients 2 years of age and older
Psoriatic Arthritis (PsA) adults adults
Ankylosing Spondylitis (AS) adults adults
Crohn’s Disease (CD) patients 6 years of age and older patients 6 years of age and older
Ulcerative Colitis (UC) patients 5 years of age and older adults
Plaque Psoriasis (Ps) adults adults
Hidradenitis Suppurativa (HS) patients 12 years of age and older adults
Uveitis (UV) patients 2 years of age and older adults

Amjevita is not approved as an interchangeable product at the pharmacy, meaning the pharmacist needs approval from the prescribing doctor to substitute Amjevita for Humira if not specified on the prescription.

Amjevita and Humira are both administered via subcutaneous injection.

See What Are Biosimilars? Top Facts You May Not Know

Related questions

References
  • U.S. Food and Drug Administration. HUMIRA Product Label. Available at https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125057s417lbl.pdf [Accessed June 26, 2023]
  • U.S. Food and Drug Administration. AMJEVITA Product Label. Available at https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761024Orig1s011lbl.pdf [Accessed June 26, 2023]
  • U.S. Food and Drug Administration. What is a Biosimilar? Available at https://www.fda.gov/media/108905/download [Accessed March 2, 2021]

Read next

Cosentyx vs Humira: How do they compare?

Both Cosentyx and Humira are available as subcutaneous injections (which means given under the skin) and may be used to treat certain inflammatory conditions such as plaque psoriasis, psoriatic arthritis, hidradenitis suppurativa, and ankylosing spondylitis. Cosentyx is also available as an IV injection that can be administered by a healthcare provider. After an initial loading dose, Humira is given every two weeks and Cosentyx every four weeks. Continue reading

Skyrizi vs Humira for plaque psoriasis - How do they compare?

In a head-to-head clinical study between Skyrizi and Humira, researchers found that Skyrizi was better than Humira at clearing moderate-to-severe plaque psoriasis in adults. At 16 weeks, 72% of patients given Skyrizi achieved 90% clearer skin compared to 47% of patients given Humira, a statistically significant outcome. Continue reading

Is Amjevita interchangeable with Humira?

Amjevita is not yet interchangeable with Humira, and the pharmacist must get approval from your doctor before they can substitute it for Humira. The approved interchangeable biosimilars for Humira are Abrilada, Amjevita, Cyltezo, Hadlima, Hulio, Hyrimoz, and Simlandi according to the FDA Purple Book as of March 2025. Continue reading

See also:

Related medical questions

Drug information

Related support groups